Harbour Antibodies BV

Harbour Antibodies BV develops advanced transgenic mouse models that enable the production of high-affinity human antibodies for therapeutic applications in biotechnology and pharmaceuticals. Founded in 2006, Harbour Antibodies BV is based in Rotterdam, Netherlands, specializing in transgenic mouse models for antibody generation. The company was acquired by Harbour Biomed in December 2016. The funding round led by Atlas Venture raised EUR 2.

50 mn, which is the total amount raised by the company through its funding efforts. Harbour Antibodies BV specializes in the development of transgenic mouse models designed to produce high-affinity human antibodies. This is achieved through two innovative strains: the H2L2 mice, which generate conventional tetrameric antibodies, and the HCAb mice, which produce heavy chain-only antibodies. These models facilitate the discovery of both human IgG and HCAb monoclonal antibodies, essential for therapeutic applications in various fields, including biotechnology and pharmaceuticals.

The company primarily markets its products to research institutions, biotechnology firms, and pharmaceutical companies in North America and Europe, thus enhancing their capacity for antibody discovery and development. Harbour Antibodies generates revenue through licensing agreements and partnerships with various biopharmaceutical companies that utilize its transgenic mouse models for antibody discovery. These B2B arrangements allow clients to secure access to either the H2L2 or HCAb mouse models under flexible terms tailored to their specific research needs, enabling them to leverage Harbour's proprietary technology in their antibody development programs. The company plans to expand its product offerings by launching new strains of transgenic mouse models designed for specific therapeutic areas, with anticipated releases in the upcoming years.

Harbour Antibodies is targeting expansion into new markets in Asia, particularly in China and Japan, which are expected to commence by 2025. The recent funding raised in December 2016 will support these growth initiatives, enhancing their research capabilities and market reach.